

Lactobacilli for the Treatment of Oral Diseases

Anja Hoffmann and Rolf Daniels*

Department of Pharmaceutical Technology, Eberhard Karls University, Tuebingen, Germany

*Corresponding author: Rolf Daniels, Department of Pharmaceutical Technology, Auf der Morgenstelle 8, 72076 Tuebingen, Germany, Tel: +49 (0) 7071 2972462; E-mail: rolf.daniels@uni-tuebingen.de

Received date: August 30, 2017; Accepted date: September 07, 2017; Published date: September 14, 2017

Copyright: © 2017 Hoffmann A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Probiotics are defined as live microorganisms that beneficially affect the host. Probiotic bacteria have been used therapeutically for years to target gastrointestinal disease by rebalancing the complex microflora. Besides the gastrointestinal tract also the oral cavity is highly colonized by bacteria and many different bacterial species are part of the microbiota in the mouth, as it offers ideal conditions for bacteria with a stable temperature, moist surface with a relatively stable pH and regular supply of nutrients. By disturbing the balance of microorganisms in the oral cavity or by extensive accumulation of plaque, the ratio of pathogenic organisms can increase and lead to oral health problems. Probiotic bacteria, like *Lactobacilli*, are a promising treatment strategy for oral diseases with a microbiological aetiology. Those include plaque-associated diseases like dental caries, which is an infectious disease with microbial processes eroding and destroying the hard dental tissue or inflammation of periodontal tissue, namely gingivitis and the more severe periodontitis. Moreover, endodontic infections, and even fungal, viral and acute bacterial infections could be treated by a probiotic therapy. The interest of probiotics in the field of oral health is growing, although it is still in its infancy. The present review addresses criteria for the selection of probiotic *Lactobacilli* strains. It encompasses existing evidence on the use of *Lactobacilli* for caries, halitosis and candidiasis, as well as for periodontal disease like Gingivitis and periodontitis.

Keywords: Probiotics; Oral health; Caries; Periodontitis; Gingivitis

Introduction

The word probiotics comes from the Greek words “pro” and “bios”, meaning ‘for life’. The term probiotics was first mentioned by Lilley and Stillwell in 1965 and was defined as the opposite of antibiotics [1]. “Organisms and substances which contribute to intestinal microbial balance” was a later definition from Parker [2]. Although this definition is still used today, this interpretation included also antibiotics, which is not commonly used today. An advancement was the interpretation from Fuller in 1989, because the importance of living cells was emphasised and the word “substances” was eliminated to avoid confusion. “A live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance” [3]. Ever since, the definition has been reworked several times and it was for instance broadened by Vrese and Schrezenmeier, who included other target location than the gut [4]. An often cited definition is the one in the WHO/FAO report from 2006, wherein probiotics were defined as: “Live microorganisms which when administered in adequate amounts confer a health benefit on the host” [5].

Probiotics are mainly used in dairy products, but they are increasingly becoming available as dietary supplements and pharmaceutical preparations. A large variety of microorganisms are classified as probiotics at present. Holzapfel [6] listed strains used as probiotics. Lactic acid bacteria are of most importance in food and nutrition, especially *Lactobacilli* and the genus *Bifidobacterium*, whereas non-lactic acid bacteria are mainly used in pharmaceutical preparations. Different *Lactobacillus* species are also found in the oral cavity and in the saliva, the most common of which are: *L. fermentum*, *L. rhamnosus*, *L. salivarius*, *L. casei*, *L. acidophilus* and *L. plantarum*

[7-9]. Three of these species are used in dairy products, but yet it is not clear, if they are detected due to frequent consumption of dairy products leading to temporary colonisation, or if the oral environment is the natural habitat [10].

If probiotics are taken orally, they are considered to be safe. A theoretical concern is that these viable bacteria move into the bloodstream and cause systemic infections. *Lactobacillus rhamnosus* GG (LGG) became available in Finland in 1990. Salminen et al. analysed blood samples in the period between 1990-2000 and did not find an increase related to the increasing probiotic use of LGG-containing commercial dairy products [11]. One case has been published that was caused by probiotic *Lactobacilli*. A *L. rhamnosus* GG strain was isolated from a liver abscess in 1999. Some cases of Endocarditis [12] or *L. rhamnosus* GG leading to bacteraemia [13] are described, but it is estimated, that only 0.05%-0.4% of these cases are due to *Lactobacilli* and bifidobacterial [14]. These *Lactobacilli* and bifidobacteria are thought to be part of the commensal microbiota, instead of administered probiotics. Most cases of probiotic bacteraemia responded well to appropriate antibiotic therapy. Common risk factors to *Lactobacillus* bacteraemia are immunosuppression, prior hospitalisation and previous antibiotic treatment [15]. Even in HIV-infected patients, the use of the probiotic *L. rhamnosus* GG was well tolerated and no adverse effects, like bacteraemic outbreaks, were observed [10]. The consumption of 1×10^{10} CFU/day was safe and well tolerated in a HIV-positive population [16]. Antibiotic resistance of *Lactobacilli* can be another safety issue. Probiotics should not carry transmissible antibiotic resistance genes [17]. *Lactobacilli* are naturally resistant to some antibiotics, as shown by Charteris [18], but this resistance is usually not of a transmissible type. Non-transmissible antibiotic resistance is usually of no safety concern. *Lactobacillus plantarum* CCUG 43738 displayed atypical phenotypic resistance to tetracycline and minocycline, from a plasmid-located tet (S) gene. This

acquired antibiotic resistance is undesirable for potential probiotics [19]. There are additional reports of acquired antibiotic resistance [20,21]. The transferal of antimicrobial resistance genes between probiotics and closely related opportunistic bacteria may take place [10]. More studies are needed, because the development of resistance to antibiotic drugs is a global issue. The US Food and Drug Administration (FDA) designation 'Generally Recognized as Safe' (GRAS) has been applied to several *Lactobacillus* strains [22] being a strong indication for safety in human consumption.

***Lactobacilli* for Oral Health**

Strain selection

The selection of appropriate probiotic strains is a key issue. In contrast to the often used dietary *lactobacilli*, indigenous bacteria offer an advantage, because they are well adjusted to the human oral ecology. Consequently, the use of orally derived probiotics is recommended. Furthermore, the binding of LAB to mucus might be necessary to show positive effects, if administered to the oral cavity. Carbohydrate-protein interactions probably play a key role in the adhesion of these proteins to mucin-bound oligosaccharides [23]. Presently, most reports on mucus binding of probiotics are in the gastrointestinal field, because this is the main field of application. Several adhesion promoting proteins in *Lactobacillus* spp. are described and summarised by Van Tassell et al. [23] and by Vélez et al. [24]. The most studied mucus-targeting bacterial adhesin is mucus-binding protein (MUB), which is produced by *L. reuteri* [25]. An adhesion-promoting protein that mediated *L. fermentum* 104R binding to both small intestinal porcine mucus and porcine gastric mucin is described by Royas et al. [26]. Moreover, some *Lactobacillus* strains adhere to Caco-2 cell cultures, which was observed by Tuomola and Salminen [27]. A mucus adhesion promoting protein, MapA, mediates the adhesion of *L. reuteri* to human intestinal epithelial cells [28]. In *L. plantarum* WCFS1 a lectin-like mannose-specific adhesin that interacts with the host intestinal tract has also been described [29]. It is expected, that bacteria, intended as oral probiotics, should adhere to and colonise surfaces of the oral cavity [30]. Yli-Knuuttila et al. investigated whether *L. rhamnosus* GG could be detected in the oral cavity after discontinuation of administration of a probiotic product. This strain could only temporally be detected, but did not colonise the oral cavity. The authors concluded, that colonisation with this strain is improbable, but possible in some cases [30]. In a clinical study, the application of a chewable tablet of *L. reuteri* ATCC 55730 (10^8 CFU/tablet) for 2 weeks did not lead to permanent colonisation of the oral cavity [31]. The consumption of probiotic yoghurt-containing *lactobacilli* did also not lead to their installation in the oral cavity [32]. In contrast, salivary *Lactobacillus* counts increased after consumption of a product containing seven different *Lactobacillus* strains [33]. *L. plantarum* 299v (Lp299v) and *L. paracasei* showed survival in saliva for 24 h. The *L. paracasei* strain bound well to a surface mimicking human dental enamel, because over 20% of the added bacteria were bound but, for Lp299v the binding was poor with below 5% [34]. *Lactobacillus* GG, incorporated into yoghurt, was consumed twice a day for 7 d. After discontinuation of consumption, the bacterium was recovered in saliva samples, and after 2 weeks the strain was still present in 8 out of 9 subjects [35].

A final aspect to consider is lactic acid production by *lactobacilli*, because this process has been implicated in enamel demineralisation and dental caries in the mouth. The ability to produce acid varies

significantly between strains and if they belong to the homofermentative or heterofermentative group [36]. Some strains, such as *L. plantarum* 299v can not only ferment carbohydrates (e.g., glucose and fructose) but also sugar alcohols (e.g., mannitol or sorbitol) leading to a decrease in pH *in-vitro*. In contrast Keller and Twetman found no evidence for an increased plaque acidity for *L. plantarum* 299 v with fructose or xylitol [37]. Strains with low metabolic activity are favourable, for example *L. paracasei* [38].

Periodontal disease

Three main factors considered for plaque-related periodontal inflammation are: a susceptible host, which is hard to address; second the presence of pathogenic species and the reduction or even absence of 'beneficial bacteria'. Today, periodontal therapies aim to reduce the bacterial threat and are based on mechanical subgingival debridement plus improvement of oral hygiene [39]. The subgingival microbiota then shifts towards a less pathogenic composition, meaning a higher proportion of Gram-positive aerobic species and fewer periodontopathogens [40]. Unfortunately, this shift is only temporary. The use of antibiotics or antiseptics for a certain time does not improve the long-term effect of periodontal therapy [41]. The use of probiotics in this field offers the possibility to restore the reduced numbers of beneficial bacteria to prevent and treat plaque-related periodontal disease. On the one hand the inhibition of specific pathogens is a possible mechanism and on the other hand the host response could be affected by probiotics.

To date, the following effects have been shown for probiotics in the field of periodontal disease. *L. salivarius* tablets reduced 5 periodontopathic bacteria in subgingival plaque after 4 weeks and the levels tended to be lower up to 8 weeks compared with placebo [42]. In a clinical trial with *L. reuteri* containing tablets the number of periodontal pathogens in the subgingival microbiota was reduced, but no significant clinical impact could be shown [43]. A *Lactobacillus* microbiota inhibited growth of *S. mutans*, *P. gingivalis* and *P. intermedia* [44]. Furthermore, antimicrobial effects against *P. gingivalis* have been described [45,46]. Co-aggregation activity of probiotic strains with oral pathogens (*Porphyromonas endodontalis*, *T. forsythia*, *Eubacterium saphenum*, *Filifactor alocis* or *P. gingivalis*) can be another mode of action [44,45,47]. Competition with periodontopathogens for the uptake of nutrients could also improve oral health [48]. Some strains produce biosurfactants, which are able to prevent the adhesion of pathogens [49]. *L. salivarius* TI 2711 administered as tablets did not significantly change the total number of bacteria in the saliva, or the number of mutans-streptococci and *lactobacilli*. Only for black-pigmented anaerobic rods, which include most periodontopathic bacteria, a significant decrease was found [50]. A promising strain is also *L. reuteri* *Prodentis*, because not only antimicrobial, but also inflammatory, effects were found along with inhibition of plaque formation [51]. The reduction of pro-inflammatory cytokines (TNF- α , IL-8) in gingival crevicular fluid can be regarded proof of concept for the application of *Lactobacillus reuteri* in a chewing gum. The modulating effect of short-term intake of probiotics on the oral immune response is dose dependent [52]. An anti-inflammatory effect of *Lactobacillus brevis*, administered as lozenge to patients with chronic periodontitis, was shown by a significant decrease in the amount of nitrite/nitrate, prostaglandin E2 and matrix metalloproteinase in saliva [53]. Different microbial species show anti-inflammatory activity [46]. Although an anti-inflammatory effect of probiotic milk drink containing *L. casei* Shirota was shown in a clinical trial, increased plaque accumulation occurred, which is

probably linked to the high sugar content [54]. The same product increased the plaque index and papilla bleeding index compared to baseline, whereas the amount of matrix metalloproteinase-3 was reduced [55]. By using a probiotic treatment (*L. reuteri*) also clinical effects were found, like a significant reduction in the gingival index and plaque scores [56]. Smokers showed a significantly greater improvement in plaque scores in a clinical trial using freeze-dried probiotic tablets of *L. salivarius* [57]. Even heat-killed *L. plantarum* decreased the depth of periodontal pockets in a randomised, double-blind, placebo-controlled clinical trial [58].

Caries

Dental caries is on the one hand associated with *S. mutans*, but also with *lactobacilli*. Indeed, *L. plantarum* and *L. paracasei* are among the species found in adult and childhood caries [59]. Various *Lactobacillus* spp. have numerical importance in carious dentine [60] and are often found in caries lesions [61]. *L. salivarius* LS 1952R induced dental caries in rats [62]. In an *in-vitro* model the combination of LGG and *S. mutans* was more cariogenic than monospecies biofilms of *S. mutans*. Therefore, LGG did not reduce the caries activity, but contributed to the caries process [63]. Another finding in this direction is that after restoration of caries, *S. mutans* and *lactobacilli* are reduced in saliva [64]. By now the role of *lactobacilli* in caries is not absolutely sure. It has been observed, that *lactobacilli* from caries-free people exert more effective inhibition of mutans-streptococci than *lactobacilli* isolated from caries-active subjects *in-vitro* [65]. *L. plantarum* 299 v and other *Lactobacillus* strains coaggregate *in-vitro* with selected oral streptococci. Coaggregation is an important factor in the development of biofilms and dental plaque [66].

Several studies have been published that hint towards an anti-caries effect of *lactobacilli*. *L. casei* ATCC 11578 is able to prevent and even decolonise the adhesion of *S. mutans* to saliva-coated hydroxyapatite by modifying the protein composition of the salivary pellicle [67]. In a clinical study using *L. paracasei* GMNL-33 a significant reduction of salivary *S. mutans* was detected after 4 weeks [68]. *L. paracasei* showed maximum interference activity against *S. mutans in-vitro*, as reported by Simark-Mattsson et al. [65]. Lozenges containing *L. brevis* CD2 taken by school children with a high caries risk, resulted in a reduction in plaque acidogenicity, salivary mutans-streptococci and bleeding on probing [69]. *L. reuteri* significantly inhibited the growth of *S. mutans*, if applied as yoghurt [70], via straws and tablets [71,72] or as chewing gum [73]. A combination of *L. sporogens*, *L. bifidum*, *L. bulgaricus*, *L. thermophilus*, *L. acidophilus*, *L. casei* and *L. rhamnosus* either as capsule or as liquid form was tested. The counts of *lactobacilli* in the saliva increased significantly, but *S. mutans* was not significantly influenced. Unfortunately, no follow-up was performed after the trial [33]. *Lactobacilli* (including *L. plantarum* 299v, *L. paracasei*, *L. reuteri*, *L. acidophilus* and *L. rhamnosus*) showed co-aggregation with mutans-streptococci *in-vitro* and inhibited the clinical mutans-streptococci [74]. In a randomised, double-blind, placebo-controlled intervention study in 594 children, milk containing LGG reduced dental caries and the counts of mutans-streptococci after 7 months. Consequently, the risk of caries was significantly reduced [75]. In another double-blind, placebo-controlled trial of milk supplemented with fluoride and/or *L. rhamnosus* the effect on primary root caries lesions was investigated. The use of milk only supplemented with *lactobacilli* showed a positive effect, as well as the fluoride, but the beneficial effect was strongest by combining both [76].

Halitosis

There is currently limited evidence to support the use of *lactobacilli* in halitosis. After taking *L. salivarius* WB21 and xylitol in tablet form daily, the scores of an organoleptic test and bleeding on probing significantly decreased after 4 weeks [77]. In a randomised double-blind, placebo-controlled cross-over trial with 25 adults a probiotic chewing gum with *L. reuteri* DSM 17938 and *L. reuteri* ATCC PTA 5289 or placebo was used. After a treatment duration of 14 days the organoleptic scores were significantly lower in the group with probiotic chewing gum [78].

Candidiasis

For candidiasis there is also little evidence available. In a randomised, double-blind, placebo-controlled study the consumption of probiotic cheese (*L. rhamnosus* GG plus *Propionibacterium freudenreichii* susp. *Shermanii* JS) led to reduced *C. albicans* counts [79]. However, in a 3 week intervention for which subjects ate 5 × 15 g cheese per day containing LGG and *L. rhamnosus* LC 705, no significant difference in the effect between the probiotic and control cheese on salivary *Candida* counts was found [80]. The administration of *L. casei* and *Bifidobacterium breve* for 20 d significantly reduced *Candida* prevalence and the level of anti-*Candida* immunoglobulin A [81]. Lozenges with *L. reuteri* *Prodentis* are available on the market and reduce the prevalence of oral *Candida* in fragile elderly people [82]. Finally, *L. plantarum* and *L. paracasei* showed some co-aggregation with *C. albicans* [83].

Discussion

The cited studies are often limited due to small sample size, lack of appropriate randomisation, blinding, duration of intervention plus follow-up and study set-up. Even fewer studies make inter-group comparison with true placebo or a negative control. The tested population is very heterogeneous and the probiotic doses applied differ up to 2 log scales. Furthermore, the vehicles used to administer the probiotics also clearly differ and might influence the outcome of the study. Typical means of probiotic administration are yoghurt, cheese [79], lozenges and tablets [72], capsules or liquids [33]. Besides, it is expected to be difficult to induce a microbiological shift or a clinical probiotic effect in a matured oral microbiological environment. The probiotics will have difficulties in colonising the mouth. A pre-treatment, to reduce the levels of indigenous microbiota, might be useful and necessary. The authors of a meta-analysis concluded, that the evidence supporting the use of probiotics to prevent or treat caries and periodontal disease is insufficient at present. In spite of the lack of evidence, they also state, that no adverse effects were reported, so there is no strong argument against using such a treatment [84].

Conclusion

Probiotic effects are strain-specific and cannot be transferred to other subspecies, or even other strains without any tests. Therefore, clear nomenclature of the evaluated strains is crucial for allocation of effects and for the judgement of efficiency. Overall, *lactobacilli* seem to be a promising way forward regarding restoration of periodontal health, especially in gingivitis, but better designed clinical trials in larger populations are needed. Moreover, combining different probiotic strains could lead to synergistic effects. This research field is in a very early state and enormous efforts are necessary to advance this promising strategy. An application in caries is questionable, as long as

the impact of *lactobacilli* on the cause and progression of the disease is not clarified.

Conflict of Interest

Anja Hoffmann reports Personal fees from Symrise AG and Rolf Daniels reports Grants from Symrise AG, both outside the submitted work. In addition, Rolf Daniels and Anja Hoffmann have a patent EP 15 184849.6 pending.

References

- Lilly DM, Stillwell RH (1965) Probiotics: Growth-Promoting Factors Produced by Microorganisms. *Science* 147: 747-748.
- Parker RB (1974) Probiotics, the other half of the antibiotic story. *Anim Nutr Health* 29: 4-8.
- Fuller R (1989) Probiotics in man and animals. *J Appl Microbiol* 66: 365-378.
- Vrese MD, Schrezenmeier J (2002) Probiotics and non-intestinal infectious conditions. *Br J Nutr* 88: 59-66.
- Food and Agriculture Organization of the United Nations (2006) Probiotics in food: Health and nutritional properties and guidelines for evaluation. *Food and nutrition paper* 85.
- Holzappel WH, Haberer P, Geisen R, Björkroth J, Schillinger U (2001) Taxonomy and important features of probiotic microorganisms in food and nutrition. *Am J Clin Nutr* 73: 365-373.
- Teanpaisan R, Dahlen G (2006) Use of polymerase chain reaction techniques and sodium dodecyl sulfate-polyacrylamide gel electrophoresis for differentiation of oral *Lactobacillus* species. *Oral Microbiol Immunol* 21: 79-83.
- Ahrne S, Nobaek S, Jeppsson B, Adlerberth I, Wold AE, et al. (1998) The normal *Lactobacillus* flora of healthy human rectal and oral mucosa. *J Appl Microbiol* 85: 88-94.
- Maukonen J, Matto J, Suihko ML, Saarela M (2008) Intra-individual diversity and similarity of salivary and faecal microbiota. *J Med Microbiol* 57: 1560-1568.
- Meurman JH, Stamatova I (2007) Probiotics: contributions to oral health. *Oral Dis* 13: 443-451.
- Salminen MK, Tynkkynen S, Rautelin H (2002) *Lactobacillus* bacteremia during a rapid increase in probiotic use of *Lactobacillus rhamnosus* GG in Finland. *Clin Infect Dis* 35: 1155-1160.
- Mackay AD, Taylor MB, Kibbler CC, Hamilton Miller JM (1999) *Lactobacillus* endocarditis caused by a probiotic organism. *Clin Microbiol Infect* 5: 290-292.
- Boyle RJ, Robins Browne RM, Tang MLK (2006) Probiotic use in clinical practice: what are the risks? *Am J Clin Nutr* 83: 1256-1264.
- Borriello SP, Hammes WP, Holzappel W (2003) Safety of probiotics that contain *lactobacilli* or *bifidobacteria*. *Clin Infect Dis* 36: 775-780.
- Salminen MK, Rautelin H, Tynkkynen S (2004) *Lactobacillus* bacteremia, clinical significance, and patient outcome, with special focus on probiotic *L. rhamnosus* GG. *Clin Infect Dis* 38: 62-69.
- Wolf BW, Wheeler KB, Ataya DG, Garleb KA (1998) Safety and tolerance of *Lactobacillus reuteri* supplementation to a population infected with the human immunodeficiency virus. *Food Chem Toxicol* 36: 1085-1094.
- Saarela M, Mogensen G, Fondén R, Mättö J, Mattila Sandholm T (2000) Probiotic bacteria: Safety, functional and technological properties. *J Biotechnol* 84: 197-215.
- Charteris WP, Kelly PM, Morelli L, Collins JK (1998) Antibiotic susceptibility of potentially probiotic *Lactobacillus* species. *J Food Prot* 61: 1636-1643.
- Huys G, D'Haene K, Swings J (2006) Genetic basis of tetracycline and minocycline resistance in potentially probiotic *Lactobacillus plantarum* strain CCUG 43738. *Antimicrob Agents Chemother* 50: 1550-1551.
- Danielsen M (2002) Characterization of the tetracycline resistance plasmid pMD5057 from *Lactobacillus plantarum* 5057 reveals a composite structure. *Plasmid* 48: 98-103.
- Stroman P, Muller CC, Sorensen KI (2003) Heat Shock Treatment Increases the Frequency of Loss of an Erythromycin Resistance-Encoding Transposable Element from the Chromosome of *Lactobacillus crispatus* CHCC3692. *Appl Environ Microbiol* 69: 7173-7180.
- Liong MT (2008) Safety of probiotics: translocation and infection. *Nutr Rev* 66: 192-202.
- Van Tassel ML, Miller MJ (2011) *Lactobacillus* adhesion to mucus. *Nutrients* 3: 613-636.
- Vélez MP, Keersmaecker D, Sigrid CJ, Vanderleyden J (2007) Adherence factors of *Lactobacillus* in the human gastrointestinal tract. *FEMS Microbiol Lett* 276: 140-148.
- Roos S, Jonsson H (2002) A high-molecular-mass cell-surface protein from *Lactobacillus reuteri* 1063 adheres to mucus components. *Microbiology* 148: 433-442.
- Rojas M, Ascencio F, Conway PL (2002) Purification and Characterization of a Surface Protein from *Lactobacillus fermentum* 104R That Binds to Porcine Small Intestinal Mucus and Gastric Mucin. *Appl Environ Microbiol* 68: 2330-2336.
- Tuomola, Elina M, Salminen SJ (1998) Adhesion of some probiotic and dairy *Lactobacillus* strains to Caco-2 cell cultures. *Int J Food Microbiol* 41: 45-51.
- Miyoshi Y, Okada S, Uchimura T, Satoh E (2006) A mucus adhesion promoting protein, MapA, mediates the adhesion of *Lactobacillus reuteri* to Caco-2 human intestinal epithelial cells. *Biosci Biotechnol Biochem* 70: 1622-1628.
- Pretzer G, Snel J, Molenaar D (2005) Biodiversity-Based Identification and Functional Characterization of the Mannose-Specific Adhesin of *Lactobacillus plantarum*. *J Bacteriol* 187: 6128-6136.
- Yli Knuuttila H, Snäll J, Kari K, Meurman JH (2006) Colonization of *Lactobacillus rhamnosus* GG in the oral cavity. *Oral Microbiol Immunol* 21: 129-131.
- Caglar E, Topcuoglu N, Cildir SK, Sandalli N, Kulekci G (2009) Oral colonization by *Lactobacillus reuteri* ATCC 55730 after exposure to probiotics. *Int J Paediatr Dent* 19: 377-381.
- Busscher HJ, Mulder AF, Van Der Mei HC (1999) In vitro Adhesion to Enamel and in vivo Colonization of Tooth Surfaces by *Lactobacilli* from a Bio-Yoghurt. *Caries Res* 33: 403-404.
- Montalto M, Vastola M, Marigo L (2004) Probiotic treatment increases salivary counts of *lactobacilli*: a double-blind, randomized, controlled study. *Digestion* 69: 53-56.
- Haukioja A, Yli Knuuttila H, Loimaranta V (2006) Oral adhesion and survival of probiotic and other *lactobacilli* and *bifidobacteria* in vitro. *Oral Microbiol Immunol* 21: 326-332.
- Meurman JH, Antila H, Salminen S (1994) Recovery of *Lactobacillus* strain GG (ATCC 53103) from saliva of healthy volunteers after consumption of yoghurt prepared with the bacterium. *Microb Ecol Health Dis* 7: 295-298.
- McBain A, Madhwani T, Eatough J, Ledder R (2009) An introduction to probiotics for dental health. *Food Sci Technol Bull* 6: 5-29.
- Keller MK, Twetman S (2012) Acid production in dental plaque after exposure to probiotic bacteria. *BMC Oral Health* 12: 44.
- Hedberg M, Hasslof P, Sjöström I, Twetman S, Stecksén Bliks C (2008) Sugar fermentation in probiotic bacteria-an in vitro study. *Oral Microbiol Immunol* 23: 482-485.
- Haffajee AD, Arguello EI, Ximenez Fyvie LA, Socransky SS (2003) Controlling the plaque biofilm. *Int Dent J* 53: 191-199.
- Ximénez Fyvie LA, Haffajee AD, Som S, Thompson M, Torresyap G, et al. (2000) The effect of repeated professional supragingival plaque removal on the composition of the supraand subgingival microbiota. *J Clin Periodontol* 27: 637-647.

41. Quirynen M, Teughels W, Soete MDE, Van Steenberghe D (2002) Topical antiseptics and antibiotics in the initial therapy of chronic adult periodontitis: microbiological aspects. *Periodontol* 28: 72-90.
42. Mayanagi G, Kimura M, Nakaya S (2009) Probiotic effects of orally administered *Lactobacillus salivarius* WB21-containing tablets on periodontopathic bacteria: a double-blinded, placebo-controlled, randomized clinical trial. *J Clin Periodontol* 36: 506-513.
43. Iniesta M, Herrera D, Montero E (2012) Probiotic effects of orally administered *Lactobacillus reuteri*-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. *J Clin Periodontol* 39: 736-744.
44. Koll Klais P, Mandar R, Leibur E, Marcotte H, Hammarstrom L, et al. (2005) Oral lactobacilli in chronic periodontitis and periodontal health: species composition and antimicrobial activity. *Oral Microbiol Immunol* 20: 354-361.
45. Pangsomboon K, Kaewnopparat S, Pitakpornpreecha T, Srichana T (2006) Antibacterial activity of a bacteriocin from *Lactobacillus paracasei* HL32 against *Porphyromonas gingivalis*. *Arch Oral Biol* 51: 784-793.
46. Connelly P (2008) *Lactobacillus plantarum*-A literature review of therapeutic benefits. *J Aust Tradit-Med So* 14: 79-82.
47. Hojo K, Nagaoka S, Ohshima T, Maeda N (2009) Bacterial Interactions in Dental Biofilm Development. *J Dent Res* 88: 982-990.
48. Smith VH, Pippin DJ (1998) Implications of resource-ratio theory for oral microbial ecology. *Eur J Oral Sci* 106: 605-615.
49. Van Hoogmoed CG, Van Der Kuijl BM, Van Der Mei HC, Busscher HJ (2000) Inhibition of *Streptococcus mutans* NS Adhesion to Glass with and without a Salivary Conditioning Film by Biosurfactant-Releasing *Streptococcus mitis* Strains. *Appl Environ Microbiol* 66: 659-663.
50. Ishikawa H, Aiba Y, Nakanishi M, Oh-hashii Y, Koga Y () Suppression of Periodontal Pathogenic Bacteria in the Saliva of Humans by the Administration of *Lactobacillus salivarius* TI2711. *J Jpn Soc Periodontol* 45: 105-112.
51. Vivekananda MR, Vandana KL, Bhat KG (2010) Effect of the probiotic *Lactobacilli reuteri* (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. *J Oral Microbiol* 2: 5344.
52. Twetman S, Derawi B, Keller M, Ekstrand K, Yucel Lindberg T, et al. (2009) Short-term effect of chewing gums containing probiotic *Lactobacillus reuteri* on the levels of inflammatory mediators in gingival crevicular fluid. *Acta Odontol Scand* 67: 19-24.
53. Della Riccia DN, Bizzini F, Perilli MG (2007) Anti-inflammatory effects of *Lactobacillus brevis* (CD2) on periodontal disease. *Oral Dis* 13: 376-385.
54. Slawik S, Staufenbiel I, Schilke R (2011) Probiotics affect the clinical inflammatory parameters of experimental gingivitis in humans. *Eur J Clin Nutr* 65: 857-863.
55. Staab B, Eick S, Knofer G, Jentsch H (2009) The influence of a probiotic milk drink on the development of gingivitis: a pilot study. *J Clin Periodontol* 36: 850-856.
56. Krasse P, Carlsson B, Dahl C, Paulsson A, Nilsson A, et al. (2005) Decreased gum bleeding and reduced gingivitis by the probiotic *Lactobacillus reuteri*. *Swed Dent J* 30: 55-60.
57. Shimauchi H, Mayanagi G, Nakaya S (2008) Improvement of periodontal condition by probiotics with *Lactobacillus salivarius* WB21: a randomized, double-blind, placebo-controlled study. *J Clin Periodontol* 35: 897-905.
58. Iwasaki K, Maeda K, Hidaka K, Nemoto K, Hirose Y, et al. (2016) Daily Intake of Heat-killed *Lactobacillus plantarum* L-137 Decreases the Probing Depth in Patients Undergoing Supportive Periodontal Therapy. *Oral Health Prev Dent* 14: 207-214.
59. Caufield PW, Schön CN, Saraithong P, Li Y, Argimón S (2015) Oral *Lactobacilli* and Dental Caries. *J Dent Res* 94: 110-118.
60. Byun R, Nadkarni MA, Chhour KL, Martin FE, Jacques NA, et al. (2004) Quantitative analysis of diverse *Lactobacillus* species present in advanced dental caries. *J Clin Microbiol* 42: 3128-3136.
61. Chhour KL, Nadkarni MA, Byun R, Martin FE, Jacques NA, et al. (2005) Molecular analysis of microbial diversity in advanced caries. *J Clin Microbiol* 43: 843-849.
62. Matsumoto M, Tsuji M, Sasaki H (2005) Cariogenicity of the probiotic bacterium *Lactobacillus salivarius* in rats. *Caries Res* 39: 479-483.
63. Schwendicke F, Dorfer C, Kneist S, Meyer Lueckel H, Paris S (2014) Cariogenic effects of probiotic *Lactobacillus rhamnosus* GG in a dental biofilm model. *Caries Res* 48: 186-192.
64. Wright JT, Cutter GR, Dasanayake AP, MacStiles H, Caufield PW (1992) Effect of conventional dental restorative treatment on bacteria in saliva. *Commun Dent Oral Epidemiol* 20: 138-143.
65. Simark Mattsson C, Emilson CG, Hakansson EG, Jacobsson C, Roos K, et al. (2007) *Lactobacillus*-mediated interference of mutans streptococci in caries-free vs. caries-active subjects. *Eur J Oral Sci* 115: 308-314.
66. Twetman L, Larsen U, Fiehn NE, Stecksens Blinks C, Twetman S (2009) Coaggregation between probiotic bacteria and caries-associated strains: an in vitro study. *Acta Odontol Scand* 67: 284-288.
67. Haukioja A, Loimaranta V, Tenovu J (2008) Probiotic bacteria affect the composition of salivary pellicle and streptococcal adhesion in vitro. *Oral Microbiol Immunol* 23: 336-343.
68. Chuang LC, Huang CS, Ou Yang LW, Lin SY (2011) Probiotic *Lactobacillus paracasei* effect on cariogenic bacterial flora. *Clin Oral Invest* 15: 471-476.
69. Campus G, Cocco F, Carta G (2014) Effect of a daily dose of *Lactobacillus brevis* CD2 lozenges in high caries risk schoolchildren. *Clin Oral Invest* 18: 555-561.
70. Nikawa H, Makihira S, Fukushima H (2004) *Lactobacillus reuteri* in bovine milk fermented decreases the oral carriage of mutans streptococci. *Int J Food Microbiol* 95: 219-223.
71. Caglar E, Kuscü OO, Cildir SK, Kuvvetli SS, Sandalli N (2008) A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli. *Int J Paediatr Dent* 18: 35-39.
72. Caglar E, Cildir SK, Ergeneli S, Sandalli N, Twetman S (2006) Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium *Lactobacillus reuteri* ATCC 55730 by straws or tablets. *Acta Odontol Scand* 64: 314-318.
73. Caglar E, Kavaloglu SC, Kuscü OO, Sandalli N, Holgersson PL, et al. (2007) Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli. *Clin Oral Invest* 11: 425-429.
74. Keller MK, Hasslof P, Stecksens Blinks C, Twetman S (2011) Co-aggregation and growth inhibition of probiotic lactobacilli and clinical isolates of mutans streptococci: an in vitro study. *Acta Odontol Scand* 69: 263-268.
75. Näse L, Hatakka K, Savilahti E (2001) Effect of Long Term Consumption of a Probiotic Bacterium, *Lactobacillus rhamnosus* GG, in Milk on Dental Caries and Caries Risk in Children. *Caries Res* 35: 412-420.
76. Petersson LG, Magnusson K, Hakestam U, Baigi A, Twetman S (2011) Reversal of primary root caries lesions after daily intake of milk supplemented with fluoride and probiotic lactobacilli in older adults. *Acta Odontol Scand* 69: 321-327.
77. Iwamoto T, Suzuki N, Tanabe K, Takeshita T, Hirofuji T (2010) Effects of probiotic *Lactobacillus salivarius* WB21 on halitosis and oral health: an open-label pilot trial. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 110: 201-208.
78. Keller MK, Bardow A, Jensdottir T, Lykkeaa J, Twetman S (2012) Effect of chewing gums containing the probiotic bacterium *Lactobacillus reuteri* on oral malodour. *Acta Odontol Scand* 70: 246-250.
79. Hatakka K, Ahola AJ, Yli Knuuttila H (2007) Probiotics reduce the prevalence of oral *Candida* in the elderly-A randomized controlled trial. *J Dent Res* 86: 125-130.
80. Ahola AJ, Yli Knuuttila H, Suomalainen T (2002) Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. *Arch Oral Biol* 47: 799-804.

-
81. Santos ALD, Jorge AOC, Santos SSFD, Silva CRGE, Leão MVP (2009) Influence of probiotics on Candida presence and IgA anti-Candida in the oral cavity. Braz J Microbiol 40: 960-964.
 82. Kraft Bodi E, Jorgensen MR, Keller MK, Kragelund C, Twetman S (2015) Effect of Probiotic Bacteria on Oral Candida in Frail Elderly. J Dent Res 94: 181-186.
 83. Gomaa EZ (2013) Antimicrobial and anti-adhesive properties of biosurfactant produced by lactobacilli isolates, biofilm formation and aggregation ability. J Gen Appl Microbiol 59: 425-436.
 84. Gruner D, Paris S, Schwendicke F (2016) Probiotics for managing caries and periodontitis: Systematic review and meta-analysis. J Dent 48: 16-25.